Notice of Change to PAR-18-185, "Development of Socially-Assistive Robots (SARs) to Engage Persons with Alzheimer's Disease (AD) and AD-Related Dementias (ADRD), and their Caregivers (R41/R42 Clinical Trial Optional)"

Notice Number: NOT-AG-19-020

Key Dates
Release Date: April 15, 2019

Related Announcements
PAR-18-185

Issued by
National Institute on Aging (NIA)

Purpose

This Notice amends the application types allowed in response to PAR-18-185 to include Renewal (Phase II) applications. It also clarifies that the inclusion of a commercialization plan is only required for Phase II, Fast-Track, and Phase IIB applications; a commercialization plan is not required for Phase I applications.

The following sections of PAR-18-185 are changed as specified below:

Part 2, Section II. Award Information

Application Types Allowed

Currently reads:
New (Phase I, Fast-Track)
Resubmission (all phases)
Phase IIB Competing Renewal (Phase IIB)
Revision

Modified to:
New (Phase I, Fast-Track)
Renewal (Phase II)
Resubmission (all phases)
Phase IIB Competing Renewal (Phase IIB)
Revision

Part 2, Section IV. Application and Submission Information

2. Content and Form of Application Submission, SBIR/STTR Information

Currently reads:

Commercialization Plan: All applicants are expected to describe a realistic plan (extending beyond the Phase II), which outlines how and when full commercialization can be accomplished. The full commercialization of the product/technology should be carried out with non-STTR funds.

Modified to:

Commercialization Plan: Phase II, Fast-Track, and Phase IIB applicants are expected to describe a realistic plan (extending beyond the Phase II), which outlines how and when full commercialization can be accomplished. The full commercialization of the product/technology should be carried out with non-STTR funds.

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Michael-David A.R.R. Kerns, M.M., M.S., Ph.D.
National Institute on Aging (NIA)
Telephone: 301-402-7713
Email: [email protected]